Addressing Concerns Regarding Verification Bias in the PRIME trial
Recent correspondence regarding the PRIME trial, specifically letters from Dr. Perera Molligoda Arachchige, Dr. lin and colleagues, and Dr.Lombardo and colleagues, has raised valid concerns about potential verification bias. These concerns center on the fact that men presenting with MRI scores of 1 to 2, coupled with low PSA density (less than 0.15 ng/mL2),were not subjected to biopsy.
It is crucial to clarify the core hypothesis guiding the PRIME trial. The study was designed to determine weather biparametric MRI (bpMRI) was non-inferior to multiparametric MRI (mpMRI) in detecting clinically significant prostate cancer. The study protocol stipulated that if both bpMRI and mpMRI yielded concordantly negative results, there would be no discernible difference in the detection of clinically significant cancer for the primary outcome.
Thus, the decision not to biopsy patients with specific MRI scores and PSA density levels was not a flaw in the study design, but rather a intentional component aligned with the primary research question. The focus was on comparing the performance of the two MRI techniques when both indicated a low probability of significant cancer, rather than definitively identifying all instances of the disease.
Acknowledging the concerns raised is important for clarity and a extensive understanding of the trial’s methodology. Though, it’s essential to interpret these considerations within the context of the study’s defined objectives and statistical framework.